Table 2 Probiotic interventions
Study | Study design | Probiotic strain(s) | Daily dose | Intervention period | Medium | Placebo treatment | Compliance |
|---|---|---|---|---|---|---|---|
Studies analysing single-strain products | |||||||
Malaguarnera et al.49 | Parallel arm | Bifidobacterium longum W11 | 5.0 × 109 CFU | 90 days | Powder containing 2.5 g fructo-oligosaccharides and vitamins B1, B2, B6 and B12 dissolved in water or milk | Vitamins B1, B2, B6 and B12 dissolved in water or milk# | Compliance cutoff 80–120% |
Kelly et al.34 | Cross-over | Lacticaseibacillus rhamnosus | 1.0 × 109 CFU | 4 weeks | Capsule containing corn starch, magnesium stearate, and silicon dioxide | Capsule containing corn starch, magnesium stearate, and silicon dioxide without the probiotic strain* | Not reported |
Pinto-Sanchez et al.50 Martin et al.51 | Parallel arm | Bifidobacterium longum NCC3001 | 1.0 × 1010 CFU | 6 weeks | Maltodextrin-based powder dissolved in lactose-free milk | Maltodextrin-based powder without the probiotic strain dissolved in lactose-free milk* | Checked but not reported |
Takada et al.36 | Parallel arm | Lacticaseibacillus casei Shirota YIT 9029 | 1.0 × 1011 CFU | 11 weeks | Fermented milk | Milk with added lactic acid without the probiotic strain# | Placebo: 97.0% Probiotic: 97.5% |
Nakagawa et al.45 | Cross-over | Lactobacillus helveticus MIKI-020 | 200 mg of live lactic acid bacteria powder, 8 times/day | 4 weeks | Tablets containing 900 mg of fermented products of L. helveticus MIKI-020, 200 mg of ground lactic acid bacteria powder, and 200 mg of theanine (and maltitol, lactose, calcium stearate, lactic acid, flavour, yeast extract) | Tablets without the probiotic strain, probiotic-derived products, and theanine (and maltitol, lactose, calcium stearate, lactic acid, flavor, yeast extract)# | Compliance <75% led to exclusion from the study |
Wang et al.39 | Parallel arm | Bifidobacterium longum 1714TM | 1.0 × 109 CFU | 4 weeks | Maltodextrin-based powder dissolved in 50 mL of water | Maltodextrin-based powder without the probiotic strain dissolved in 50 mL of water* | Not reported |
Adikari et al.35 | Parallel arm | Lacticaseibacillus casei Shirota | 3.0 × 1010 CFU | 8 weeks | Cultured milk (80 mL) mixed with orange fruit juice (120 mL) | 200 mL of orange fruit juice# | Not reported |
Ho et al.46 | Parallel arm | Lactiplantibacillus plantarum PS128 | 3.0 × 1010 CFU | 30 days | Microcrystalline cellulose capsules | Microcrystalline cellulose capsules without the probiotic strain* | Compliance >98% |
Asaoka et al.48 | Parallel arm | Bifidobacterium breve MCC1274 | 2.0 × 1010 CFU | 24 weeks | Mainly maize starch-based powder | Maize starch-based powder without the probiotic strain# | Placebo: 96.1 ± 5.2% Probiotic: 97.2 ± 3.5% |
Kikuchi-Hayakawa et al.47 | Cross-over | Lacticaseibacillus paracasei Shirota YIT 9029 | 1.0 × 1011 CFU | 4 weeks | Fermented milk | Non-fermented milk with added lactic acid without the probiotic strain# | Placebo: 99.7% Probiotic: 100% |
Mutoh et al.44 | Parallel arm | Bifidobacterium breve M-16V | 2.0 × 1010 CFU | 6 weeks | Maltodextrin-based powder formed into a stick | Maltodextrin-based powder+ | Placebo: 99.1% Probiotic: 97.9% |
Li et al.56 | Parallel arm | Pediococcus acidilactici CCFM6432 | 1.0 × 109 CFU | 30 days | Powder, consumed directly or dissolved in water | Powder+ | Checked but exact details not reported (6 participants were excluded due to compliance issues) |
Studies analysing multi-strain products | |||||||
Tillisch et al.31 | Parallel arm | Bifidobacterium lactis | 1.25 × 1010 CFU, 2 doses/day | 4 weeks | Fermented milk | A non-fermented milk without probiotics+ | Compliance <75% led to exclusion from the study |
Lactobacillus bulgaricus | 1.2 × 109 CFU, 2 doses/day | ||||||
Lactococcus lactis | Not reported, 2 doses/day | ||||||
Streptococcus thermophilus | 1.2 × 109 CFU, 2 doses/day | ||||||
Bagga et al.37 Bagga et al.38 | Parallel arm | Bifidobacterium bifidum W23 | 7.5 × 109 CFU | 4 weeks | Freeze-dried powder of maize starch and maltodextrin dissolved in milk or lukewarm water | Freeze-dried powder of maize starch and maltodextrin without the probiotic strains dissolved in milk or lukewarm water+ | Checked but not reported |
Bifidobacterium lactis W51 | |||||||
Bifidobacterium lactis W52 | |||||||
Lacticaseibacillus casei W56 | |||||||
Lacticaseibacillus paracasei W20 | |||||||
Lactiplantibacillus plantarum W62 | |||||||
Lactobacillus acidophilus W22 | |||||||
Lactococcus lactis W19 | |||||||
Ligilactobacillus salivarius W24 | |||||||
Papalini et al.32 Bloemendaal et al.33 | Parallel arm | Bifidobacterium bifidum W23 | 5.0 × 109 CFU | 28 days | Powder consisting of maize starch, maltodextrin, vegetable protein and a mineral mix dissolved in water or milk | Powder consisting of maize starch, maltodextrin, vegetable protein and a mineral mix dissolved in water or milk* | Not reported |
Bifidobacterium lactis W51 | |||||||
Bifidobacterium lactis W52 | |||||||
Lacticaseibacillus paracasei W56 | |||||||
Lactobacillus acidophilus W37 | |||||||
Lactococcus lactis W19 | |||||||
Lactococcus lactis W58 | |||||||
Levilactobacillus brevis W63 | |||||||
Ligilactobacillus salivarius W24 | |||||||
Parallel arm | Bifidobacterium breve | 4.5 × 109 CFU | 28 days | Maltose-based powder dissolved in water, milk, juice or similar | A commercially available baby milk-powder dissolved in water, milk, juice or similar# | Not reported | |
Bifidobacterium lactis NCIMB 30435 | |||||||
Bifidobacterium lactis NCIMB 30436 | |||||||
Lacticaseibacillus paracasei | |||||||
Lactiplantibacillus plantarum | |||||||
Lactobacillus acidophilus | |||||||
Lactobacillus helveticus | |||||||
Streptococcus thermophilus | |||||||
Edebol Carlman et al.41 Rode et al.42 Rode et al.43 | Cross-over | Bifidobacterium longum R0175 | 7.0 × 107 CFU | 4 weeks | Inulin- and fructose-based powder with zinc, magnesium, potassium, glutathione, lactoferrin, sweeteners, dyes and aroma dissolved in a glass of water | Fructose-based powder with sweeteners, dyes and aroma dissolved in a glass of water# | Compliance >90% |
Lactiplantibacillus plantarum R1012 | 8.0 × 108 CFU | ||||||
Lactobacillus helveticus R0052 | 2.0 × 109 CFU | ||||||
Schaub et al.53 Yamanbaeva et al.54 Schneider et al.55 | Parallel arm | Bifidobacterium breve NCIMB 30441 | 9.0 × 109 CFU | 31 days | Maltose-based powder dissolved in any cold, non-carbonated drink | Maltose-based powder without the probiotic strains dissolved in any cold, non-carbonated drink* | Placebo: 86% Probiotic: 83% |
Bifidobacterium lactis NCIMB 30435 | |||||||
Bifidobacterium lactis NCIMB 30436 | |||||||
Lacticaseibacillus paracasei NCIMB 30439 | |||||||
Lactiplantibacillus plantarum NCIMB 30437 | |||||||
Lactobacillus acidophilus NCIMB 30442 | |||||||
Lactobacillus helveticus | |||||||
Streptococcus thermophilus NCIMB 30438 | |||||||
Parallel arm | Lacticaseibacillus rhamnosus DSM 32550 | 5.1 × 109 CFU at study start, 1.4 × 109 CFU at study end; input ratio of the different strains was 13.3: 3.6: 8.0: 1 | 3 months | Powder containing 2.5 g fructo-oligosaccharides, 5 mg zinc, maltodextrin dissolved in lukewarm water | Maltodextrin dissolved in lukewarm water# | Not reported | |
Lactiplantibacillus plantarum DSM 34532 | |||||||
Bifidobacterium lactis DSM 32269 | |||||||
Bifidobacterium longum DSM 32946 | |||||||